Literature DB >> 16981460

[Experimental study on treatment of allergic asthma guinea pigs with different fractions of Modified Zhisousan].

Nai-yu Xu1, Zhen-lun Gu, Mei-lin Xie, Wen-xuan Zhou, Ci-yi Guo.   

Abstract

OBJECTIVE: To study the effects of different fractions of Modified Zhisousan (MZ, MZC, MZS) on the contents of nitric oxide (NO), endothelin-1 (ET-1) and eosinophilia (EOS) in the allergic asthma guinea pigs and observe the pathology changes of lung tissue.
METHODS: The number of EOS in the blood and bronchialveolar lavage fluid (BALF) was counted by Wright staining. The contents of ET-1 and No in serum and BALF were analyzed by RIA and nitric acid reductase method. The guinea pig lungs were observed under the optical and electron microscope.
RESULTS: The number of EOS and the contents of ET-1 and NO in model group were higher than those in control group (P < 0.01). The pathological changes of lung were obvious. The number of EOS and the contents of ET-1 and NO were descended remarkably (P < 0.05 or P < 0.01) and the pathological changes in the lung tissue were lightened obviously in MZ and MZC groups, but MZS group had no such effects.
CONCLUSION: MZC is the effective part of MZ and the anti-asthmatic mechanisms ware related to its significant reduction in contents of ET-1, NO, EOS and the damage of lung tissue possibly.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981460

Source DB:  PubMed          Journal:  Zhong Yao Cai        ISSN: 1001-4454


  2 in total

Review 1.  Clinical Effects and Safety of Zhi Sou San for Cough: A Meta-Analysis of Randomized Trials.

Authors:  Ningchang Cheng; Jia Zhu; Pinpin Ding
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-17       Impact factor: 2.629

2.  Effects of Modified Zhisou Powder on Airway Mucus Production in Chronic Obstructive Pulmonary Disease Model Rats with Cold-Dryness Syndrome.

Authors:  Gao Zhen; Wang Jing; Jing Jing; Dan Xu; Li Zheng; Fengsen Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-07-18       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.